clinical trial · NCT07146386
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
Shanghai Huilun Pharmaceutical Co., Ltd.·phase3·not yet recruiting·n = 728
Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia With Lower Urinary Tract SymptomsH077 sustained-release tabletSilodosin capsules Control Group
brief summary
This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic hyperplasia.
started
Aug 1, 2025
primary completion
Jan 1, 2027
completion
Mar 1, 2027
last updated
Aug 28, 2025
official title
A Randomized, Double-blind, Controlled, Non-inferiority Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of H077 Sustained-release Tablets Versus Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol